Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis.

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Cat allergy is a significant cause of allergic rhinoconjunctivitis and a risk factor for asthma.
• Sensitivity to cats contributes substantially to the overall burden of allergic disease.

Purpose of the Study:

• To review the current data on a novel therapeutic approach for treating cat allergy.
• To evaluate the efficacy and safety of Cat Peptide Antigen Desensitisation (Cat-PAD).

Main Methods:

• Cat-PAD is a mixture of seven small peptides derived from the major cat allergen Fel d 1.
• The therapy is designed to induce immunological tolerance by interacting with antigen-presenting cells and regulatory T cells.
• Peptides are too small to cross-link IgE on mast cells and basophils, thus avoiding immediate allergic reactions.

Main Results:

• Clinical studies show Cat-PAD significantly reduces allergic rhinoconjunctivitis symptoms.
• A short course of four injections over 12 weeks demonstrated sustained treatment effects.
• The therapeutic effect persisted for 2 years post-treatment initiation.

Conclusions:

• Cat-PAD represents a novel, well-tolerated, and promising therapeutic option for individuals with cat allergy.
• Further data from an international Phase III study will confirm its efficacy and tolerability in real-world settings.